Immatics N.V. $IMTX Holdings Lifted by Wellington Management Group LLP

Wellington Management Group LLP grew its holdings in Immatics N.V. (NASDAQ:IMTX) by 5.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,647,852 shares of the company’s stock after purchasing an additional 85,960 shares during the period. Wellington Management Group LLP owned about 1.23% of Immatics worth $16,693,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. T. Rowe Price Investment Management Inc. increased its position in Immatics by 10.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock worth $225,322,000 after purchasing an additional 2,075,987 shares during the last quarter. RTW Investments LP raised its position in shares of Immatics by 29.7% in the fourth quarter. RTW Investments LP now owns 11,433,354 shares of the company’s stock valued at $120,050,000 after purchasing an additional 2,617,737 shares during the period. Perceptive Advisors LLC raised its holdings in Immatics by 10.7% in the 4th quarter. Perceptive Advisors LLC now owns 10,383,456 shares of the company’s stock worth $109,026,000 after acquiring an additional 1,000,000 shares during the period. Vestal Point Capital LP lifted its position in shares of Immatics by 1.6% during the 3rd quarter. Vestal Point Capital LP now owns 6,350,000 shares of the company’s stock worth $54,102,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Jefferies Financial Group Inc. lifted its holdings in shares of Immatics by 323.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 5,059,551 shares of the company’s stock worth $53,125,000 after buying an additional 3,864,636 shares during the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on IMTX shares. Jefferies Financial Group set a $17.00 price objective on shares of Immatics in a research report on Tuesday, August 25th. Weiss Ratings downgraded shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Finally, Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of Immatics in a research report on Tuesday, May 19th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Immatics presently has a consensus rating of “Moderate Buy” and an average target price of $20.60.

Insider Transactions at Immatics

In related news, Director Perceptive Advisors Llc purchased 863,060 shares of Immatics stock in a transaction that occurred on Wednesday, August 26th. The shares were acquired at an average price of $8.69 per share, with a total value of $7,499,991.40. Following the completion of the transaction, the director directly owned 11,246,516 shares of the company’s stock, valued at $97,732,224.04. This represents a 8.31% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Immatics Price Performance

Shares of NASDAQ:IMTX opened at $9.56 on Monday. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -5.14 and a beta of 1.33. Immatics N.V. has a fifty-two week low of $5.67 and a fifty-two week high of $12.41. The firm’s 50 day simple moving average is $9.42 and its 200 day simple moving average is $10.01.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Immatics had a negative return on equity of 47.41% and a negative net margin of 495.71%.The firm had revenue of $10.44 million for the quarter, compared to the consensus estimate of $12.42 million. Equities research analysts expect that Immatics N.V. will post -2 earnings per share for the current year.

Immatics Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.